STOCK TITAN

AVAH Secures Three-Year $275M Securitization, Strengthens Cash Flexibility

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Aveanna Healthcare (NASDAQ: AVAH) filed an 8-K announcing a Seventh Amendment to its receivables securitization facility. The amendment raises the maximum availability to $275 million, subject to the existing borrowing-base, and extends the scheduled termination date to three years from 25 June 2025. The change strengthens near-term liquidity and pushes out maturities without adding new restrictive covenants. The full text of the amendment is filed as Exhibit 10.1.

Positive

  • Increase of the receivables facility limit to $275 million, providing additional liquidity headroom
  • Extension of the facility’s scheduled termination date to three years, reducing near-term refinancing risk

Negative

  • None.

Insights

TL;DR: Bigger, longer facility lifts liquidity—net positive.

The $275 million cap represents a meaningful increase in low-cost working-capital funding, improving cash flexibility during a rising-rate environment. Extending tenor to three years removes short-dated refinancing risk and signals lender confidence. Because the securitization is asset-backed, incremental borrowing should not materially strain covenants. Investors should view the change as a modest credit positive that could smooth earnings volatility tied to receivable timing.

TL;DR: Liquidity up, leverage optionality widens—watch usage.

While the amendment enhances headroom, actual benefit hinges on utilization. Higher draws would raise secured debt and priority claims on receivables, potentially subordinating unsecured lenders. Absence of disclosed pricing leaves cost impact unknown. Still, the three-year horizon and maintained borrowing-base requirements cap risk. Overall effect skews slightly positive but warrants monitoring of draw levels and receivables performance.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
0001832332false00018323322025-06-252025-06-25

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 25, 2025

 

 

img25596635_0.jpg

Aveanna Healthcare Holdings Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40362

81-4717209

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

400 Interstate North Parkway SE

 

Atlanta, Georgia

 

30339

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 770 441-1580

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.01 per share

 

AVAH

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 1.01 Entry into a Material Definitive Agreement.

On June 25, 2025, Aveanna Healthcare LLC and Aveanna SPV I, LLC (collectively, the "Loan Parties"), each of which is a wholly owned subsidiary of Aveanna Healthcare Holdings Inc., a Delaware corporation (the "Company"), entered into a seventh amendment (the "Seventh Amendment") to the Loan Parties' Receivables Financing Agreement (the "Securitization Facility") with a bank. The Seventh Amendment amended the Securitization Facility principally to increase the maximum amount available to $275.0 million (the "Facility Limit"), subject to maintaining certain borrowing base requirements. The Seventh Amendment also, among other things, provides for an extension to the scheduled termination date of the Securitization Facility to three years from the effective date of the Seventh Amendment.

 

The foregoing description of the Seventh Amendment is only a summary and is qualified in its entirety by reference to the full text of the Seventh Amendment and the complete text of the Securitization Facility, as amended by the Seventh Amendment, which are filed together as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

Description

10.1*

Seventh Amendment to the Receivables Financing Agreement, dated June 25, 2025, by and among, Aveanna SPV I, LLC, Aveanna Healthcare LLC, and a bank

104

 

Cover Page Interactive Data File (formatted as Inline XBRL)

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Aveanna Healthcare Holdings Inc.

 

 

 

 

Date:

June 27, 2025

By:

/s/ Matthew Buckhalter

 

 

 

Matthew Buckhalter
Chief Financial Officer

(Principal Financial Officer)

 


FAQ

Why did AVAH amend its receivables financing agreement?

To enlarge liquidity capacity and extend the term; the facility limit rose to $275 million and maturity now runs three years from 25 June 2025.

What is the new maximum borrowing capacity for AVAH under the securitization facility?

The Seventh Amendment increased the facility limit to $275 million, subject to borrowing-base requirements.

How long is Aveanna Healthcare’s updated securitization facility term?

The scheduled termination date was extended to three years from the amendment’s effective date of 25 June 2025.

Does the amendment add new financial covenants?

The filing states borrowing-base requirements remain; no additional covenants were disclosed in the 8-K.

What exhibit contains the full text of the amendment?

The complete Seventh Amendment is filed as Exhibit 10.1 to the current report.